A Secret Weapon For SGC-CBP30
123). It is notable that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for lack of Gls in MYC-induced mouse liver tumours40. This implies that GLS2 could confer resistance to GLS1-certain inhibitors, like the allosteric inhibitor BPTES or CB-839, which resistance may be hypothetically prevented by the use of a twin GL